We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

95 hedge funds and large institutions have $348M invested in iShares US Pharmaceuticals ETF in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 37 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.74% more ownership

Funds ownership: 145.48% → 148.22% (+2.7%)

0% more capital invested

Capital invested by funds: $348M → $348M (+$439K)

2% less funds holding

Funds holding: 97 → 95 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

35% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 37

Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
2.37%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
7
Increased
24
Reduced
37
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$13.4M
2
MML Investors Services
MML Investors Services
Massachusetts
+$5.29M
3
CS
Credit Suisse
Switzerland
+$1.48M
4
Bank of America
Bank of America
North Carolina
+$851K
5
IWM
IHT Wealth Management
Illinois
+$613K

Top Sellers

1
MTWSIF
Mivtachim The Workers Social Insurance Fund
Israel
-$5.78M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.7M
3
MIAN
Mariner Independent Advisor Network
Kansas
-$5.5M
4
TSS
Two Sigma Securities
New York
-$4.95M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
51
Karp Capital Management
California
$430K -$18.2K -360 -4%
PAG
52
Private Advisor Group
New Jersey
$407K +$34.7K +687 +9%
GLRA
53
Gerald L. Ray & Associates
Texas
$402K +$22.7K +450 +6%
FAAS
54
First Allied Advisory Services
California
$351K +$105K +2,076 +45%
Creative Planning
55
Creative Planning
Kansas
$348K +$3.64K +72 +1%
TFA
56
Transamerica Financial Advisors
Florida
$340K +$22.9K +453 +7%
OC
57
Oppenheimer & Co
New York
$334K +$24.7K +489 +8%
BF
58
BOK Financial
Oklahoma
$311K +$11.5K +228 +4%
JMPWA
59
JP Morgan Private Wealth Advisors
California
$307K – – –
IA
60
IFP Advisors
Florida
$293K -$257K -5,079 -47%
CB
61
Commerce Bank
Missouri
$284K -$7.58K -150 -3%
HSBC Holdings
62
HSBC Holdings
United Kingdom
$263K – – –
AG
63
Advisor Group
Arizona
$250K -$54.3K -1,074 -18%
CIBC World Market
64
CIBC World Market
Ontario, Canada
$240K – – –
Cambridge Investment Research Advisors
65
Cambridge Investment Research Advisors
Iowa
$213K -$29.4K -582 -12%
RSA
66
Robertson Stephens Advisors
California
$212K – – –
SWP
67
Stratos Wealth Partners
Ohio
$212K – – –
EWM
68
Edge Wealth Management
New York
$206K – – –
AFG
69
Arkansas Financial Group
Arkansas
$201K +$196K +3,882 New
Citigroup
70
Citigroup
New York
$182K -$4.55K -90 -3%
CPA
71
Clear Perspective Advisors
Illinois
$147K – – –
PNC Financial Services Group
72
PNC Financial Services Group
Pennsylvania
$118K +$12.6K +249 +12%
US Bancorp
73
US Bancorp
Minnesota
$104K – – –
ADL
74
Asset Dedication LLC
California
$83K – – –
CTC
75
Central Trust Company
Missouri
$83K – – –
1 2
3
4 5

IHE Hedge Fund Activity: Q2 2017 in Review

95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2017, worth a combined $348M — up 0.13% from $348M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IHE and 7 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 24 added.

The largest buyer was Morgan Stanley, adding an estimated $13.4M. The largest seller was Mivtachim The Workers Social Insurance Fund, exiting entirely with an estimated $5.78M sold.

  • 95 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2017, down from 97 in Q1 2017.
  • Funds reported $348M of iShares US Pharmaceuticals ETF stock for Q2 2017, up 0.13% quarter-over-quarter.
  • 7 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2017 and 9 closed out, a net change of -2 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2017 was Morgan Stanley, an estimated $13.4M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2017 was Mivtachim The Workers Social Insurance Fund, an estimated $5.78M sold.

Based on aggregated 13F filings for Q2 2017.